Goodrx is trading 7.04% down at $3.30 after disclosing its first- and second-quarter 2026 financial statements should no longer be relied upon.
- The company identified understated Pharma Direct revenue and expects to report material weaknesses in financial controls.
- The filing was reported November 2, 2026, after the regular session; supplied price context shows a $3.55 close. No after-hours volume information was provided.